March 7, 2026 •
The 1982 Tanner Report: Early Internal Evidence of NDMA Formation The 1982 Tanner Report stands as the foundational document in the case against GSK. It…
February 24, 2026 •
Strategic Framework: Deconstructing Bayer's 'Five-Point Plan' for Litigation Containment SECTION 1 of 14: Strategic Framework: Deconstructing Bayer’s ‘Five-Point Plan’ for Litigation Containment Bayer AG’s legal…
February 22, 2026 • Ekalavya Hansaj
The 'Points Program': Gamifying Prescriptions in China's Public Hospitals Corporate corruption often manifests as complex financial instruments or shell companies. In the case of Pfizer…
February 13, 2026 • Ekalavya Hansaj
The Zyprexa Papers: A $1.4 Billion Off-Label Marketing Settlement The following investigative review examines the 2009 Zyprexa settlement involving Eli Lilly and Company. The Settlement…
February 11, 2026 • Ekalavya Hansaj
Antitrust Warfare: The Metsera 'Killer Acquisition' Lawsuit Against Novo Nordisk The acquisition of Metsera Inc. stands as a defining moment in Pfizer’s corporate history during…
February 10, 2026 • Ekalavya Hansaj
Vioxx Scandal: Data Suppression and the $4.85 Billion Settlement The trajectory of rofecoxib, commercially branded as Vioxx, represents a catastrophic failure of corporate ethics and…
Enter the 14-digit code sent to your email.